Ovarian Cancer

Women with ovarian cancer appeared to be at greater risk for anxiety, depression and adjustment disorder within the first 2 years of diagnosis than women in the general population, study results showed.

The addition of paclitaxel to cisplatin in a hyperthermic intraperitoneal chemotherapy regimen doubled PFS among women with advanced epithelial ovarian cancer undergoing interval debulking surgery, study results showed.

Rucaparib significantly prolonged PFS compared with chemotherapy for women with BRCA-mutated advanced, relapsed ovarian cancer, according to a study presented at the virtual Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Olaparib maintenance significantly extended 5-year PFS for women with advanced BRCA-positive ovarian cancer, according to results presented at the virtual Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

The FDA granted priority review to pafolacianine sodium injection as an intraoperative adjunct to help identify ovarian cancer during surgery, according to the agent’s manufacturer.

The FDA granted fast track designation to GEN-1 for treatment of advanced ovarian cancer, according to the agent’s manufacturer.

Upfront cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy may be a viable treatment for certain older women with ovarian cancer, according to results of a study published in Annals of Surgical Oncology.

Lorna Rodriguez-Rodriguez, MD, PhD, has been invited to join The Carol Emmott Fellowship Class of 2021.

Melissa K. Frey, MD, does not believe a woman who has just been diagnosed with ovarian cancer should be responsible for telling her relatives they also may be at risk.

A longitudinal study revealed the mechanism of early puberty as a driver of breast cancer risk. It was the top story in hematology/oncology last week.